Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Osmetech starts clinical trials of warfarin assay:

This article was originally published in Clinica

Executive Summary

Molecular diagnostics firm Osmetech has initiated clinical trials of its eSensor 2C9/VKOR test, assessing its use in identifying patients at risk for increased sensitivity to warfarin. Patients' genetic make-up may influence how they respond to the blood thinner. The trials are intended to support the company's 510(k) application for US marketing clearance for the 2C9/VKOR assay together with its eSensor XT-8 instrument. Pasadena, California-based Osmetech said that it expects to gain US approval and launch the genetic test in the first half of 2008. eSensor, and electrochemistry-based array system, is already launched in the US for cystic fibrosis carrier detection.

You may also be interested in...



Industry Asks If Small Business Loan Relief Applies To Companies With Equity Investors

A medtech industry group is asking the Trump administration to clarify if small medical device companies that have equity investors qualify for small business loans and forgiveness under the coronavirus relief package.

Amarin's Vascepa May Face Generic Competition In US Next Year After Patents Ruled Invalid

Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.

Grail’s Liquid Biopsy Can Detect Numerous Deadly Cancer Types Early

Grail announced results from an initial validation study that showed its early-detection blood test could identify 12 of the deadliest cancers with a low rate of false-positive results.

Topics

UsernamePublicRestriction

Register

MT050179

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel